IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors

IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors

Background High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective.Methods I...

Full description

Bibliographic Details
Main Authors: Sjoerd H van der Burg, Ramon Arens, Thorbald van Hall, Elham Beyranvand Nejad, Jan Willem Kleinovink, Camilla Labrie, Marit J van Elsas, Hans-Willi Mittrücker, Kees L M C Franken, Sylvia Heink, Thomas Korn
Format: Article
Language:English
Published: BMJ Publishing Group 2021-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/4/e002460.full

Internet

https://jitc.bmj.com/content/9/4/e002460.full

Similar Items